Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The audit was completed with zero critical and zero major observations
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
This approval reflects company’s unwavering commitment that the quality assurance
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The facility will manufacture its Herceptin biosimilar, Tuznue
Subscribe To Our Newsletter & Stay Updated